Clinical Trial Update: Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial evaluating allogeneic NK-cell therapy with chemotherapy for patients after surgical resection of pancreatic ductal adenocarcinoma (sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Allogeneic NK cell therapy (ex vivo-cultured allogeneic natural killer (NK) cells)
• Chemotherapy (chemotherapy)

Snippet

Sponsor: Medigen Biotechnology Corporation | Conditions: Pancreatic Carcinoma Stage II, Cholangiocarcinoma Resectable | Phase 1, Phase 2 | Status: RECRUITING